
m is 0 or 1;

z is an integer selected from 1-30, inclusive;

L is a linker; and

BA is a binding agent.

[0007a] One aspect is directed to a Compound of Formula (**III**)



(**III**);


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein


R4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

either both **Rx** are hydrogen or both **Rx** are fluoro; ~~and~~

SP is -C(O)-C_1-C_{10}-alkylene-C(O)-;~~, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-**X1**- where **X1** is attached to **L** in Formula (**III**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to **L** in Formula (**III**), -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to~~




~~**L** in Formula (**III**),~~ ~~where the point of attachment at the piperazine nitrogen is attached to **L** in Formula (**III**), -CH_2-NH- where the nitrogen is attached to **L** in~~




~~Formula (**III**),~~ ~~where the nitrogen is attached to **L** in Formula (**III**), -(C_1-C_{10}-alkylene)-N**R50**C(O)-(C_1-C_{10}-alkylene)-N**R50a**- where the terminal N**R50a** is attached to **L** in Formula (**III**), -C(O)-(C_1-C_{10}-alkylene)-N**R50**C(O)-(C_1-C_{10}-alkylene)-N**R50a**- where the terminal N**R50a** is attached to **L** in Formula (**III**) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or~~


more hydroxy, -C(O)-N(**R**^{5})-C_1-C_{10}-alkylene-C(O)NH-**X**^{2}- where **X**^{2} is attached to **L** in




Formula (**III**), or -where **X**^{4} is attached to **L** in Formula (**III**); or both **R**^{x} are fluoro; and **SP** is -C(O)-C_1-C_{10}-alkylene-C(O)-, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-**X**^{1b}- where **X**^{1b} is attached to **L** in Formula (**III**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-**X**^{1b}- where **X**^{1b} is attached to **L** in Formula (**III**),



where the point of attachment at the piperazine nitrogen is attached to **L** in Formula (**III**), -CH_2-NH- where nitrogen is attached to **L** in Formula (**III**),



where nitrogen is attached to **L** in Formula (**III**), -(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**), -C(O)-(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(**R**^{5})-(C_1-C_{10}-alkylene)-C(O)NH-**X**^{2}- where **X**^{2} is attached to **L** in Formula (**III**), or



where **X**^{4} is attached to **L** in Formula (**III**); and

X^{1} is -N(C_{1-6}alkyl)-;

X^{1b} is -S-, -NH-, or -N(C_{1-6}alkyl)-;

X^{2} is -NH-;

X^{3} is -CH_2-, **X**^{3} is -CH_2-O-(C_1-C_{10}-alkylene)-C(O)- where the C(O) is attached to **X**^{4}, or **X**^{3} is -C(O)-;

X^{4} is -O-;

R^{5} is hydrogen, -OH, -OCH_3, or C_{1-6}alkyl;






R^{50} and **R**^{50a} are independently hydrogen or C_1-C_6-alkyl;

R^{d}, **R**^{e}, and **R**^{f} are independently hydrogen, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH_2O**R**^{g}, where each **R**^{g} is independently -CH_2C(O)OH or -CH_2C(O)O(alkyl);

~~**m** is zero or one;~~

~~**z** is an integer selected from one to thirty, inclusive;~~

L is a linker of the formula $–L^1-L^2-(L^3)_{0-1}$-; where $\mathbf{L^1}$ is attached to **BA** and $\mathbf{L^3}$ is attached to **SP**;


$\mathbf{L^1}$ is a reactive group residue selected from the group consisting of , , , , and  where  is a bond to the binding agent;

$\mathbf{L^2}$ is a connecting linker; and

$\mathbf{L^3}$, when present, is a self-immolative linker; and

BA is a binding agent.

[0008] A second example is directed to a Compound according to Formula (**I**):




(**I**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof,

wherein:


$\mathbf{R^4}$ is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

a) both $\mathbf{R^x}$ are hydrogen; and

$\mathbf{R^3}$ is -C(O)$\mathbf{R^Z}$; -(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}}\mathbf{R^{50b}}$; -$CH_2NH_2$; or ;

$\mathbf{R^Z}$ is -C_{4-10}-alkylene-C(O)OH; -(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}}\mathbf{R^{50b}}$


where each C_1-C_{10}-alkylene is independently optionally substituted with one or more

hydroxy;  where where **Ar** is optionally substituted aryl or heteroaryl; or N**R**^{15}**R**^{15a};


R^{15} is H or C_1-C_6alkyl and **R**^{15a} is -(C_1-C_{10}-alkylene)-SH or -(C_{1-6}-alkylene)-C(O)$NHNH_2$;

b) both **R**^{x} are fluoro; and

R^{3} is -C(O)**R**^{Z}**;** -(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}**R**^{50b}; -CH_2NH_2; or



;

R^{Z} is -C_{4-10}-alkylene-C(O)OH; -(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}**R**^{50b} where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy;  where where **Ar** is optionally substituted aryl or heteroaryl; or N**R**^{16}**R**^{16a};

$\mathbf{R^d}$, $\mathbf{R^e}$, and $\mathbf{R^f}$ are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or $-CH_2O\mathbf{R^g}$, where each $\mathbf{R^g}$ is independently $-CH_2C(O)OH$ or $-CH_2C(O)O$(alkyl); and


m is 0 or 1;

RG is a reactive group;

$\mathbf{L^2}$ is connecting linker; and

$\mathbf{L^3}$, when present, is a self-immolative linker.

[0009a] Another aspect is directed to a Compound of Formula (**II**)





(**II**);

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,


wherein

$\mathbf{R^4}$ is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

either both $\mathbf{R^x}$ are hydrogen or both $\mathbf{R^x}$ are fluoro;


SP is -C(O)-C_1-C_{10}-alkylene-C(O)-;~~, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-$\mathbf{X^1}$- where $\mathbf{X^1}$ is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**), -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**),~~  ~~where the point of attachment at the piperazine nitrogen is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**), -CH_2-NH- where nitrogen is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**),~~  ~~where nitrogen is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**), -(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}}$- where the terminal N$\mathbf{R^{50a}}$ is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**), -C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}}$- where the terminal N$\mathbf{R^{50a}}$ is attached to $(\mathbf{L^3})_{0-1}$ in Formula (**II**) and where each C_1-C_{10}-alkylene is independently~~

optionally substituted with one or more hydroxy, -C(O)-N(**R**^{5})-C_1-C_{10}-alkylene-C(O)NH-**X**^{2}-




where **X**^{2} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), or where **X**^{4} is attached to **L**^{3} in Formula (**II**); or


both **R**^{x} are fluoro; **SP** is -C(O)-C_1-C_{10}-alkylene-C(O)-, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-**X**^{1b}- where **X**^{1b} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-**X**^{1b}-




where **X**^{1b} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), where the point of



attachment at the piperazine nitrogen is attached to (**L**^{3})$_{0-1}$ in Formula (**II**),



-CH_2-NH- where nitrogen is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), where nitrogen is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), -(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(**R**^{5})-(C_1-C_{10}-alkylene)-C(O)NH-



X^{2}- where **X**^{2} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**), or where **X**^{4} is attached to (**L**^{3})$_{0-1}$ in Formula (**II**); and

X^{1} is -N(C_{1-6}alkyl)-;

X^{1b} is -S-, -NH-, or -N(C_{1-6}alkyl)-;

X^{2} is -NH-;

X^{3} is -CH_2-, **X**^{3} is -CH_2-O-(C_1-C_{10}-alkylene)-C(O)- where the C(O) is attached to **X**^{4}, or **X**^{3} is -C(O)-;








X^{4} is -O-;

~~R^5 is hydrogen, -OH, $-OCH_3$, or C_{1-6}alkyl;~~

~~R^{50} and R^{50a} are independently hydrogen or C_1-C_6-alkyl;~~

~~R^d, R^e, and R^f are independently hydrogen, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or $-CH_2OR^g$, where each R^g is independently $-CH_2C(O)OH$ or $-CH_2C(O)O$(alkyl);~~




~~m is zero or one;~~






RG is a reactive group selected from the group consisting of , , , , , , and ;

L^2 is a connecting linker; and







L^3, when present, is a self-immolative linker.





~~**[0009b]** Another aspect is directed to a compound selected from the group consisting of~~




~~2b~~	
~~2f~~	
~~2g~~	





~~2j~~	
~~2k~~	
~~2l~~	
~~2m~~	
~~2n~~	





~~or a mixture thereof~~

~~2q~~	
~~LP1~~	
~~LP2~~	
~~LP3~~	
~~LP4~~	
~~LP5~~	


~~LP6~~	
~~LP7~~	
~~LP8~~	
~~LP12~~	

~~LP13~~	
~~LP20~~	
~~LP21~~	

~~LP24~~	
~~LP25~~	
~~LP26~~	
~~LP27~~	

~~LP28~~	
~~LP29~~	
~~LP30~~	 ~~and~~
~~LP31~~	

[~~0009c~~0009b] Another aspect is directed to a Compound according to Formula (**I**)



(**I**);


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,


wherein

R^{4} is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

a) both $\mathbf{R^x}$ are hydrogen or both $\mathbf{R^x}$ are fluoro; ~~and~~

$\mathbf{R^3}$ is -C(O)$\mathbf{R^Z}$; and ~~-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}R^{50b}}$; -CH_2NH_2;~~


~~or~~  ~~;~~

$\mathbf{R^Z}$ is -$C_{4\text{-}10}$-alkylene-C(O)OH~~;~~ ~~-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}R^{50b}}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy;~~  ~~; or N$\mathbf{R^{15}R^{15a}}$;~~


~~$\mathbf{R^{15}}$ is hydrogen or C_1-C_6alkyl and $\mathbf{R^{15a}}$ is -(C_1-C_{10}-alkylene)-SH or -($C_{1\text{-}6}$-alkylene)-C(O)NHNH$_2$; or~~


~~b) both $\mathbf{R^x}$ are fluoro; and~~

~~$\mathbf{R^3}$ is -C(O)$\mathbf{R^Z}$; -(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}R^{50b}}$; -CH_2NH_2; or~~



~~;~~

~~$\mathbf{R^Z}$ is -$C_{4\text{-}10}$-alkylene-C(O)OH; -(C_1-C_{10}-alkylene)-N$\mathbf{R^{50}}$C(O)-(C_1-C_{10}-alkylene)-N$\mathbf{R^{50a}R^{50b}}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy;~~  ~~; or N$\mathbf{R^{16}R^{16a}}$;~~








~~$\mathbf{R^{16}}$ is hydrogen or C_1-C_6alkyl and $\mathbf{R^{16a}}$ is -(C_1-C_{10}-alkylene)-SH, -(C_1-C_{10}-alkylene)-NH$_2$, -(C_1-C_{10}-alkylene)-NH($C_{1\text{-}6}$alkyl),~~  ~~, or -($C_{1\text{-}6}$-alkylene)-C(O)NHNH$_2$; and~~






~~each $\mathbf{R^{50}}$, $\mathbf{R^{50a}}$, and $\mathbf{R^{50b}}$ are independently hydrogen or C_1-C_6-alkyl;~~




~~one of $\mathbf{R^c}$, $\mathbf{R^d}$, $\mathbf{R^e}$, and $\mathbf{R^f}$ is -$CH_2O\mathbf{R^g}$ and the others are independently hydrogen, -OH, hydroxyalkyl, -C(O)OH, or -$CH_2O\mathbf{R^g}$, where each $\mathbf{R^g}$ is independently -($C_{1\text{-}6}$-alkylene)-C(O)OH or -($C_{1\text{-}6}$-alkylene)-C(O)O(alkyl); or one of $\mathbf{R^c}$, $\mathbf{R^d}$, $\mathbf{R^e}$, and $\mathbf{R^f}$ is hydroxyalkyl and the others are hydrogen; and~~

~~$\mathbf{m}$ is zero to one.~~

[0009d] Another aspect is directed to a compound selected from the group consisting of


1e	
1g	
1h	
101a	
101b	
101c	
101d	

~~102c~~	
~~102d~~	
~~102e~~	
~~102f~~	
~~104a~~	


~~104b~~	
~~105a~~	 ~~and~~
~~105b~~	 ~~; or~~

~~a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.~~

~~[0009e] Another aspect is directed to a Compound selected from the group consisting of~~




, and




~~or a mixture thereof;~~


~~where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof~~


~~[0009f] Another aspect is directed to a Compound according to one of the following formulae~~







~~or a mixture thereof;~~












or a mixture thereof






~~or a mixture thereof~~



where **BA** comprises an antibody or antigen binding fragment having the following structure




where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; **R** is C_{2-4}-alkylene; and **n** is an integer selected from two to four, inclusive.

[00010] Another example is directed to pharmaceutical compositions comprising the Compound of Formula (**I**), Formula I-P, Formula I-P-1, Formula (**III**-P), Formula III-P-1, Formula (3000), or Formula (**III**) and a pharmaceutically acceptable carrier, diluent, and/or excipient.


[00011] Another example is directed to methods useful for the treatment of various diseases, disorders, or conditions comprising administering a Compound of Formula I, Formula I-P, Formula I-P-1, Formula (**III**-P), Formula III-P-1, Formula (3000), or Formula (**III**) or administering a pharmaceutical composition comprising a Compound of Formula I, Formula I-P, Formula I-P-1, Formula (**III**-P), Formula III-P-1, Formula (3000), or Formula (**III**) and a pharmaceutically acceptable carrier, diluent, and/or excipient.

[0011a] Another aspect is directed to use of a compound of Formula (III) as defined herein, or the compound as defined herein in the manufacture of a medicament for the treatment of a disease, disorder, or condition associated with glucocorticoid receptor signaling wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.


[0011b] Another aspect is directed to a Compound selected from the group consisting of




1c




~~1d~~




~~1e~~




~~1g~~




~~1h~~




~~1i~~




~~1j~~




~~101a~~




~~101b~~




~~101c~~




~~101d~~




~~102c~~




~~102d~~




~~102e~~



~~102f~~




104a and




104b

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


[0011c] Another aspect is directed to a Compound selected from the group consisting of




2a




2b




~~2c~~




~~2d~~




~~2e~~




~~2f~~




~~2g~~




~~2j~~




~~2k~~




~~2l~~




~~2m~~




~~2n~~




~~2q~~




~~2r~~




~~2s~~




~~LP1~~




~~LP2~~




~~LP3~~




~~LP4~~




~~LP5~~




~~LP6~~




~~LP7~~




~~LP8~~




~~LP12~~



~~LP13~~




LP20 and




LP21


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


[0011d] Another aspect is directed to a Compound selected from the group consisting of


Ab
H
N
O
O
O
O
N
N
N
O
O
NH
O
O
O
O
O
O
O
O
H
N
O
N
H
H
N
O
O
N
H
O
O
O
O
O
O
H
H
H
HO
H
O
NH
O
NH2
z



Ab
H
N
N
N
N
O
O
O
O
O
NH
O
O
O
O
O
O
O
O
N
H
O
N
H
O
O
O
O
O
O
H
H
H
HO
O
NH
O
NH2
z

;



Ab
H
N
N
N
N
O
O
O
O
O
NH
O
O
O
O
O
O
O
O
N
H
O
N
H
O
O
O
O
O
O
H
H
H
OH
O
NH
O
NH2
z


Ab
N
H
O
NH
N
N
N
O
NH
NH2
OH
z


;


Ab
N
H
O
NH
N
N
N
O
NH
NH2
OH
z

;



; and




;


wherein **Ab** is an antibody or an antigen binding fragment thereof; and


z is an integer from one to four.

[0011e] Another aspect is directed to a Compound selected from the group consisting of





;


Ab
H
N
O
O
O
O
N
N
N
O
O
NH
O
O
O
O
O
O
O
O
H
N
O
N
H
H
N
O
O
N
H
O
O
O
O
O
O
H
H
H
HO
H
O
NH
O
NH2
z




;



Ab
S
O
O
N
O
O
O
O
O
O
O
O
O



Ab
S
O
N
O
O
O
O
O
O
O
H
N
O
N
H
O
H
N
O
N
H
O
O
O
O
O
H
H
H
HO
H
O
NH
HO
HO
OH
OH
OH
NH
H2N
O
z

;



Ab
S
O
N
O
O
O
N
H
O
H
N
O
O
N
H
N
H
O
O
O
O
H
H
H
HO
H
O
NH
O
NH2
z


;







;



Ab
H
N
O
N
N
N
O
NH
O
H
N
O
NH
NH2
F
H
H
H
OH
z



Ab
H
N
O
N
N
N
O
NH
O
H
N
O
NH
NH2
F
H
H
H
OH
z


;



Ab
H
N
O
N
N
N
O
O
O



Ab
H
N
O
N
N
N
O
O
O



Ab
N
H
O
S
S
N
H
O
O
O
O
H
H
H
F
F
HO
O
z


Ab
N
H
O
S
S
N
O
O
O
O
H
H
H
F
F
HO
O
z



Ab
N
H
O
O
O
O
O
O
O
O
O
N
N
N
H
O
NH
H
H
O
N
H
O
S
S
N
H
O
O
O
O
H
H
H
F
F
HO
O
z


Ab
N
H
O
O
O
O
O
O
O
N
N
N
H
H
O
NH
O
O
O
N
H
O
S
S
N
O
O
O
O
O
H
H
H
F
F
HO
O
z



Ab
N
H
O
NH
N
N
N
H
H
O
O
O


Ab
N
H
O
NH
OH
HO
F
NH2
z

;


Ab
H
N
O
N
N
H
H
O
O
O
O
O
O
O
O
H
N
O
O
O
O
O
O
O
O
H
N
(S)
O
O
HO
O
H
N
O
O
H
N
O
O
NH
O
NH2
OH
O
H
N
O
O
O
O
O
H
H
F
F
HO
O
z

~~; and~~



~~wherein **Ab** is an antibody or an antigen binding fragment thereof; and~~

~~**z** is an integer from one to four.~~

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0010] FIGS. 1A, 1B, and 1C, and 2 show GR activation of steroid-ADCs as tested in Example 7.

[0011] FIG. 3 shows Scheme 1. Synthesis of Spacer-Budesonide 1c-1e, 1g-1i, and 1j-1l.

DETAILED DESCRIPTION


A. DEFINITIONS

[0012] As used herein, "alkyl" refers to a monovalent and saturated hydrocarbon radical moiety. Unless specified otherwise, Alkyl is unsubstituted and can be linear, branched, or cyclic, *i.e.*, cycloalkyl. Alkyl includes, but is not limited to, those having 1–20 carbon atoms, *i.e.*, $C_{1–20}$ alkyl; 1–12 carbon atoms, *i.e.*, $C_{1–12}$ alkyl; 1–8 carbon atoms, *i.e.*, $C_{1–8}$ alkyl; 1–6 carbon atoms, *i.e.*, $C_{1–6}$ alkyl; and 1–3 carbon atoms, *i.e.*, $C_{1–3}$ alkyl. Cycloalkyl, which is a subset of alkyl includes, but is not limited to, groups having 3–20 carbon atoms, *i.e.*, $C_{3–20}$ alkyl; 3–12 carbon atoms, *i.e.*, $C_{3–12}$ alkyl; 3-10 carbon atoms, *i.e.*, $C_{3–10}$ alkyl; 3–8 carbon

CLAIMS

What is claimed is:

1. A Compound of Formula (**III**)



(**III**);


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein


R4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

either both **Rx** are hydrogen or both **Rx** are fluoro; ~~and~~


SP is -C(O)-C_1-C_{10}-alkylene-C(O)-;~~, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-**X1**- where **X1** is attached to **L** in Formula (**III**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to **L** in Formula (**III**), -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to~~



~~**L** in Formula (**III**),~~ ~~where the point of attachment at the piperazine nitrogen is attached to **L** in Formula (**III**), -CH_2-NH- where the nitrogen is attached to **L** in~~




~~Formula (**III**),~~ ~~where the nitrogen is attached to **L** in Formula (**III**), -(C_1-C_{10}-alkylene)-N**R50**C(O)-(C_1-C_{10}-alkylene)-N**R50a**- where the terminal N**R50a** is attached to **L** in Formula (**III**), -C(O)-(C_1-C_{10}-alkylene)-N**R50**C(O)-(C_1-C_{10}-alkylene)-N**R50a**- where the terminal N**R50a** is attached to **L** in Formula (**III**) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(**R5**)-C_1-C_{10}-alkylene-C(O)NH-**X2**- where **X2** is attached to **L** in Formula (**III**), or~~




~~where **X4** is attached to **L** in Formula (**III**); or~~


both R^x are fluoro; and **SP** is -C(O)-C_1-C_{10}-alkylene-C(O)-, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-X^{1b}- where X^{1b} is attached to **L** in Formula (**III**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-X^{1b}- where X^{1b} is attached to **L** in Formula (**III**),



where the point of attachment at the piperazine nitrogen is attached to **L** in Formula (**III**), -CH_2-NH- where nitrogen is attached to **L** in Formula (**III**),



where nitrogen is attached to **L** in Formula (**III**), -(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to **L** in Formula (**III**), -C(O)-(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to **L** in Formula (**III**) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(R^5)-(C_1-C_{10}-alkylene)-C(O)NH-X^2- where X^2 is attached to **L** in Formula (**III**), or



where X^4 is attached to **L** in Formula (**III**); and

X^1 is -N(C_{1-6}alkyl)-;

X^{1b} is -S-, -NH-, or -N(C_{1-6}alkyl)-;

X^2 is -NH-;

X^3 is -CH_2-, X^3 is -CH_2-O-(C_1-C_{10}-alkylene)-C(O)- where the C(O) is attached to X^4, or X^3 is -C(O)-;

X^4 is -O-;

R^5 is hydrogen, -OH, -OCH_3, or C_{1-6}alkyl;

R^{50} and R^{50a} are independently hydrogen or C_1-C_6-alkyl;


R^d, R^e, and R^f are independently hydrogen, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH_2OR^g, where each R^g is independently -CH_2C(O)OH or -CH_2C(O)O(alkyl);

m is zero or one;

z is an integer selected from one to thirty, inclusive;

L is a linker of the formula –L^1-L^2-(L^3)$_{0-1}$-; where $\mathbf{L^1}$ is attached to **BA** and $\mathbf{L^3}$ is attached to **SP**;

L[1] is a reactive group residue selected from the group consisting of




where is a bond to the binding agent;

L[2] is a connecting linker; and

L[3], when present, is a self-immolative linker; and

BA is a binding agent.

2. A Compound of Formula (**II**)



(**II**);


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein






R[4] is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;


either both **R**[x] are hydrogen or both **R**[x] are fluoro;

SP is -C(O)-C_1-C_{10}-alkylene-C(O)-;~~, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-**X**[1]- where **X**[1] is attached to (**L**[3])$_{0-1}$ in Formula (**II**), -C(O)-N(H)-(C_1-C_{10}-alkylene)-S- where sulfur is attached to (**L**[3])$_{0-1}$ in Formula (**II**), -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-S- where sulfur is~~



~~attached to (**L**[3])$_{0-1}$ in Formula (**II**),~~ ~~where the point of attachment at the piperazine nitrogen is attached to (**L**[3])$_{0-1}$ in Formula (**II**), -CH_2-NH- where nitrogen is~~

attached to (L^3)$_{0-1}$ in Formula (II),  where nitrogen is attached to (L^3)$_{0-1}$ in Formula (II), -(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to (L^3)$_{0-1}$ in Formula (II), -C(O)-(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to (L^3)$_{0-1}$ in Formula (II) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(R^5)-C_1-C_{10}-alkylene-C(O)NH-X^2- where X^2 is attached to (L^3)$_{0-1}$ in Formula (II), or  where X^4 is attached to L^3 in Formula (II); or both R^x are fluoro; SP is -C(O)-C_1-C_{10}-alkylene-C(O)-, -C(O)-N(C_{1-6}alkyl)-C_1-C_{10}-alkylene-X^{1b}- where X^{1b} is attached to (L^3)$_{0-1}$ in Formula (II), -C(O)-N(H)-(C_1-C_{10}-alkylene)-X^{1b}- where X^{1b} is attached to (L^3)$_{0-1}$ in Formula (II),  where the point of attachment at the piperazine nitrogen is attached to (L^3)$_{0-1}$ in Formula (II), , -CH_2-NH- where nitrogen is attached to (L^3)$_{0-1}$ in Formula (II),  where nitrogen is attached to (L^3)$_{0-1}$ in Formula (II), -(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to (L^3)$_{0-1}$ in Formula (II), -C(O)-(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where the terminal NR^{50a} is attached to (L^3)$_{0-1}$ in Formula (II) and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(R^5)-(C_1-C_{10}-alkylene)-C(O)NH-

~~X^2 - where X^2 is attached to $(L^3)_{0-1}$ in Formula (II), or~~  ~~where X^4 is attached to $(L^3)_{0-1}$ in Formula (II); and~~

~~X^1 is -N(C_{1-6}alkyl) -;~~

~~X^{1b} is -S -, -NH -, or -N(C_{1-6}alkyl) -;~~

~~X^2 is -NH -;~~

~~X^3 is -CH_2-, X^3 is -CH_2-O-(C_1-C_{10}-alkylene)-C(O)- where the C(O) is attached to X^4, or X^3 is -C(O) -;~~








~~X^4 is -O -;~~

~~R^5 is hydrogen, -OH, -OCH_3, or C_{1-6}alkyl;~~

~~R^{50} and R^{50a} are independently hydrogen or C_1-C_6-alkyl;~~

~~R^d, R^e, and R^f are independently hydrogen, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -$CH_2O$$R^g$, where each R^g is independently -CH_2C(O)OH or -CH_2C(O)O(alkyl);~~

~~m is zero or one;~~

RG is a reactive group selected from the group consisting of , , , , , , and ;

L^2 is a connecting linker; and

L^3, when present, is a self-immolative linker.

3. The Compound of Claim 1 or 2, where R^4 is linear or branched alkyl.


4. The Compound of Claim 1 or 2, where R^4 is aryl.


5. The Compound of Claim 1 or 2, where R^4 is arylalkyl.

6. The Compound of Claim 1 or 2, where R^4 is N-containing heterocycloalkyl.

7. The Compound of any one of Claims 1-6, where R^4 is in the (*R*)-configuration.

~~8. The Compound of any one of Claims 1-7, where~~

~~both **R**^{x} are hydrogen; and **SP** is -C(O)-C$_{1}$-C$_{10}$-alkylene-C(O)-, -C(O)-N(C$_{1-6}$alkyl)-C$_{1}$-C$_{10}$-alkylene-**X**^{1}- where **X**^{1} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-N(H)-(C$_{1}$-C$_{10}$-alkylene)-S- where sulfur is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-N(C$_{1-6}$alkyl)-(C$_{1}$-C$_{10}$-alkylene)-S- where sulfur is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50}C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50}C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**) and where each C$_{1}$-C$_{10}$-alkylene is independently optionally substituted with one or more hydroxy, -C(O)-N(**R**^{5})-C$_{1}$-C$_{10}$-alkylene-C(O)NH-**X**^{2}- where **X**^{2} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), or~~  ~~where **X**^{4} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**); or~~

~~both **R**^{x} are fluoro; and **SP** is -C(O)-N(C$_{1-6}$alkyl)-C$_{1}$-C$_{10}$-alkylene-**X**^{1b}- where **X**^{1b} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-N(H)-(C$_{1}$-C$_{10}$-alkylene)-**X**^{1b}- where **X**^{1b} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**),~~  ~~where the point of attachment at the piperazine nitrogen is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50}C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**), -C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50}C(O)-(C$_{1}$-C$_{10}$-alkylene)-N**R**^{50a}- where the terminal N**R**^{50a} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**) and where each C$_{1}$-C$_{10}$-alkylene is independently optionally substituted with one or more hydroxy, or -C(O)-N(**R**^{5})-(C$_{1}$-C$_{10}$-alkylene)-C(O)NH-**X**^{2}- where **X**^{2} is attached to **L** in Formula (**III**) or (**L**^{3})$_{0-1}$ in Formula (**II**).~~

~~9. The Compound of any one of Claims 1-8, where **SP** is -C(O)-C$_{1}$-C$_{10}$-alkylene-C(O)-~~

~~.~~

~~10.~~8. The Compound of any one of Claims 1-~~9~~7, where **SP** is -C(O)-C$_{2}$-C$_{5}$-alkylene-C(O)-

.

~~11.~~9. The Compound of any one of Claims 1-~~10~~8, where **SP** is -C(O)-CH_2CH_2-C(O)-.


~~12. The Compound of any one of Claims 1-8, where **SP** is -C(O)-N(**R**^{5})-C_1-C_{10}-alkylene-C(O)NH-**X**^{2}-.~~


~~13. The Compound of any one of Claims 1-8 or 12, where **SP** is -C(O)-N(**R**^{5})-C_1-C_5-alkylene-C(O)NH-NH-.~~


~~14. The Compound of any one of Claims 1-8, 12, or 13, where **SP** is -C(O)-N(**R**^{5})-CH_2-C(O)NH-NH-.~~


~~15. The Compound of any one of Claims 1-8 or 12-14, where **R**^{5} is hydrogen or C_1-$_6$alkyl.~~


~~16. The Compound of any one of Claims 1-8 or 12-15, where **R**^{5} is hydrogen or -CH_3.~~


~~17. The Compound of any one of Claims 1-8, where **SP** is~~  ~~.~~

~~18. The Compound of any one of Claims 1-8, where **SP** is~~  ~~and **m** is one.~~


~~19. The Compound of any one of Claims 1-8, where **SP** is~~  ~~, **m** is one, and **R**^{f} is hydrogen or -OH.~~

~~20. The Compound of any one of Claims 1-8, where **SP** is~~  ~~, **m** is one, and **R**^{f} is hydrogen.~~


21. The Compound of any one of Claims 1-8, where **SP** is , **m** is one, and R^f is -OH.

22. The Compound of any one of Claims 1-8, where **SP** is  and **m** is zero.


23. The Compound of any one of Claims 1-8 or 17-22, where **SP** is

 and X^3 is -CH_2-.

24. The Compound of any one of Claims 1-8 or 17-22, where **SP** is

 and X^3 is -CH_2-O-(C_1-C_{10}-alkylene)-C(O)-.

25. The Compound of any one of Claims 1-8 or 17-22, where **SP** is

 and X^3 is -C(O)-.

26. The Compound of any one of Claims 1-8 or 17-25, where R^d and R^e are independently hydrogen or -OH.

27. The Compound of any one of Claims 1-8 or 17-25, where R^d and R^e are hydrogen.

28. The Compound of any one of Claims 1-8 or 17-25, where R^d and R^e are -OH.

29. The Compound of any one of Claims 1-8, where **SP** is -(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}-.

~~30. The Compound of any one of Claims 1-8, where **SP** is -(linear C_1-C_3-alkylene)-N**R**^{50}C(O)-(linear C_1-C_3-alkylene)-N**R**^{50a}-.~~

~~31. The Compound of any one of Claims 1-8, where **SP** is -C(O)-(C_1-C_{10}-alkylene)-N**R**^{50}C(O)-(C_1-C_{10}-alkylene)-N**R**^{50a}- and where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy.~~

~~32. The Compound of any one of Claims 1-8, where **SP** is -(branched C_1-C_6-alkylene)-N**R**^{50}C(O)-(C_1-C_6-hydroxy-alkylene)-N**R**^{50a}-.~~

~~33. The Compound of any one of Claims 1-8 or 29-32, where **R**^{50} and **R**^{50a} are independently hydrogen or methyl.~~

~~34. The Compound of any one of Claims 1-8 or 29-32, where **R**^{50} and **R**^{50a} are each hydrogen.~~

~~35. The Compound of any one of Claims 1-8 or 29-32, where **R**^{50} and **R**^{50a} are each methyl.~~

~~36.~~10. The Compound of any one of Claims 1-~~35~~9, where both **R**^{x} are hydrogen.

~~37. The Compound of any one of Claims 1-8, where both **R**^{x} are hydrogen and **SP** is -C(O)-N(H)-(C_1-C_{10}-alkylene)-S- or -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-S-.~~

~~38. The Compound of any one of Claims 1-8, where both **R**^{x} are hydrogen and **SP** is -C(O)-N(C_{1-3}alkyl)-C_1-C_{10}-alkylene-**X**^{1}-.~~

~~39. The Compound of any one of Claims 1-8 or 38, where both **R**^{x} are hydrogen and **SP** is -C(O)-N(C_{1-3}alkyl)-C_2-C_5-alkylene-**X**^{1}-.~~

~~40. The Compound of any one of Claims 1-8, 38, or 39, where both **R**^{x} are hydrogen and **SP** is -C(O)-N(C_{1-3}alkyl)-CH_2CH_2-**X**^{1}-.~~

~~41. The Compound of any one of Claims 1-8, 38, or 39, where both **R**^{x} are hydrogen and **SP** is -C(O)-N(CH_3)-C_2-C_5-alkylene-N(CH_3)-.~~

~~42. The Compound of any one of Claims 1-8 or 38-41 where both **R**^{x} are hydrogen and **SP** is -C(O)-N(CH_3)-CH_2CH_2-N(CH_3)-.~~

43.11. The Compound of any one of Claims 1-359, where both **R**^{x} are fluoro.

~~44. The Compound of any one of Claims 1-8, where both **R**^{x} are fluoro and **SP** is -C(O)-N(H)-(C_1-C_{10}-alkylene)-**X**^{1b}- or -C(O)-N(C_{1-6}alkyl)-(C_1-C_{10}-alkylene)-**X**^{1b}-.~~


~~45. The Compound of Claim 44, where **SP** is -C(O)-N(H)-(C_1-C_6-alkylene)-**X**^{1b}- or -C(O)-N(C_{1-6}alkyl)-(C_1-C_6-alkylene)-**X**^{1b}-.~~

~~46. The Compound of Claim 44 or 45, where **X**^{1b} is sulfur.~~

~~47. The Compound of Claim 44 or 45, where **X**^{1b} is -NH- or -N(C_{1-6}-alkyl)-.~~


~~48. The Compound of Claim 44 or 45, where **X**^{1b} is -NH- or -N(CH_3)-.~~








~~49. The Compound of any one of Claims 1-8, where both **R**^{x} are fluoro and **SP** is~~








~~.~~



~~50. The Compound of any one of Claims 1-7, where **SP** is -CH_2-NH-.~~

~~51. The Compound of any one of Claims 1-7, where **SP** is~~  ~~.~~

~~52. The Compound of any one of Claims 1-7, where both **R**^{x} are hydrogen or both **R**^{x} are fluoro and **SP** is~~  ~~,~~  ~~,~~  ~~,~~  ~~,~~  ~~,~~  ~~,~~  ~~,~~

~~ ,  ,  ,  , -CH_2-NH- ,~~

~~ or ;~~

~~or both **R**[x] are fluoro and **SP** is~~  ~~or~~  ;

~~and where the left side point of attachment in the above **SP** structures is attached to **L** or ($\mathbf{L^3}$)$_0$ 1.~~

~~53.~~12. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~52~~11, where **z** is selected from one to ten, inclusive.


~~54.~~13. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~53~~11, where **z** is selected from two to four, inclusive.

~~55.~~14. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~54~~13, where **z** is four.


~~56.~~15. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~54~~13, where **z** is two.

~~57.~~16. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~56~~15, where **BA** comprises an antibody, an antibody fragment, or an antigen binding fragment thereof.

~~58.~~17. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~57~~15, where **BA** comprises an antibody or antigen binding fragment thereof having the following structure

 where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; **R** is C_{2-4}-alkylene, **n** is an integer selected from one to ten, inclusive, and **z** is an integer selected from one to ten, inclusive.

~~59.~~18. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~59~~15, where **BA** comprises an antibody or antigen binding fragment having the following structure




where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; **R** is C_{2-4}-alkylene; and **n** is an integer selected from two to four, inclusive.


~~60.~~19. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~59~~18, where **BA** comprises an antibody or antigen binding fragment thereof that binds macrophage scavenger receptor 1 (MSR1).

~~61.~~20. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~60~~19, where **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-, where $\mathbf{L^1}$ is attached to **BA** and $\mathbf{L^2}$ is attached to **SP**; and where $\mathbf{L^1}$ is a reactive group residue; and $\mathbf{L^2}$ is connecting linker.

~~62.~~21. The Compound of Formula (**III**) of any one of Claims 1 or 3-~~60~~19, where **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-$\mathbf{L^3}$-.


~~63.~~22. The Compound of Formula (**III**) of Claim ~~61~~ 20 or ~~62~~ 21 where $\mathbf{L^1}$ is selected from






and


where is a bond to BA.~~or a~~




~~regioisomer or mixture of isomers thereof;~~




;






~~or a regioisomer or mixture of isomers thereof;~~





~~or a stereoisomer or mixture of stereoisomers thereof, where S refers to the sulfur atom on a cysteine residue through which the reactive group residue is attached to **BA**; and~~




~~where N refers to the nitrogen atom on a lysine residue through which the reactive group residue is attached to **BA**.~~


~~64.~~23. The Compound of Formula (**II**) of any one of Claims 2-~~52~~11, where **RG** is selected from the group consisting of , , and .


~~65.~~24. The Compound of Formula (**II**) of any one of Claims 2-~~52~~11, where **RG** is .


~~66.~~25. The Compound of Formula (**II**) of any one of Claims 2-~~52~~11, where **RG** is .

~~67.~~26. The Compound of Formula (**II**) of any one of Claims 2-~~52~~11, where **RG** is .

~~68.~~27. The Compound of any one of claims 1-~~67~~26, where for the Compound of Formula (**III**), **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-$\mathbf{L^3}$)$_{0\text{-}1}$-; and where

$\mathbf{L^3}$ in the Compound of Formula (**II**) or (**III**) is  where the -NH-group is attached to $\mathbf{L^2}$, when **SP** is -C(O)-C_1-C_{10}-alkylene-C(O)-; or




~~$\mathbf{L^3}$ in the Compound of Formula (**II**) or (**III**) is~~  ~~where the -NH- group is attached to $\mathbf{L^2}$, when **SP** is -C(O)-N($C_{1\text{-}3}$alkyl)-C_1-C_{10}-alkylene-$\mathbf{X^1}$-, -C(O)-N($C_{1\text{-}3}$alkyl)-C_1-C_{10}-alkylene-$\mathbf{X^{1b}}$- where $\mathbf{X^{1b}}$ is -NH- or -N($C_{1\text{-}6}$alkyl)-, -C(O)-N(H)-(C_1-C_{10}-alkylene)-$\mathbf{X^{1b}}$-~~




~~where X^{1b} is -NH- or -N(C_{1-6}alkyl)-,~~  ~~, -(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}-, -C(O)-(C_1-C_{10}-alkylene)-NR^{50}C(O)-(C_1-C_{10}-alkylene)-NR^{50a}- where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxyl or -C(O)-N(R^5)-C_1-C_{10}-alkylene-C(O)NH-X^2-; or~~






L^3 in the Compound of Formula (**II**) or (**III**) is absent.


~~69.~~28. The Compound of any one of claims 1-~~68~~27, where for the Compound of Formula (**III**), **L** is -**L^1**-**L^2**-**L^3**)$_{0-1}$-; and where **L^2** in the Compound of Formula (**II**) or (**III**) comprises PEG, a di-peptide residue, a tripeptide residue, a tetrapeptide residue, a pentapeptide residue, -C(O)CH_2CH_2C(O)-, a cyclodextrin (CD) residue, or -$CH_2CH_2CH_2CH_2CH_2$C(O)-, or any combination thereof.



~~70.~~29. The Compound of any one of claims 1-~~68~~27, where for the Compound of Formula (**III**) **L** is -**L^1**-**L^2**-(**L^3**)$_{0-1}$-; and where **L^2** in the Compound of Formula (**II**) or (**III**) comprises


, , ,


, , ,

, , , , ,

,



-C(O)CH_2CH_2C(O)NH-, , ,





,



, or a cyclodextrin residue (**CD**); or any combination thereof.


~~71.~~30. The Compound of any one of claims 1-~~68~~27, where for the Compound of Formula (**III**), **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-$\mathbf{L^3}$)$_{0\text{-}1}$-; and where $\mathbf{L^2}$ in the Compound of Formula (**II**) or (**III**) comprises



,



,



,



,



,


,


,



,



,



,



or a **CD** residue, or any combination thereof.


~~72.~~31. The compound of any one of claims ~~69~~28-~~71~~30, wherein **CD** is selected from the group consisting of


,


,



,


,




,


and





.


73.32. The Compound of any one of Claims 1-6726, where for the Compound of Formula (**III**), **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-$\mathbf{L^3}$)$_{0\text{-}1}$-; and where -$\mathbf{L^2}$-($\mathbf{L^3}$)$_{0\text{-}1}$- in the Compound of Formula (**II**) or (**III**) comprises









































or




~~74.~~33. The compound of claim 1, wherein the compound is




wherein the linker-payload is connected to Ab through a side chain of a cysteine residue; or a stereoisomer or mixture of stereoisomers thereof;







or a mixture thereof;





~~or a stereoisomer or mixture of stereoisomers thereof;~~




~~or a stereoisomer or mixture of stereoisomers thereof;~~








~~or a mixture thereof~~



~~where L^1 is a reactive group residue comprising a triazole moiety;~~

~~or a stereoisomer or mixture of stereoisomers thereof~~







where **BA** comprises an antibody or antigen binding fragment having the following structure














where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; **R** is C_{2-4}-alkylene; and **n** is an integer selected from two to four, inclusive.







~~75.~~34. The compound of claim ~~74~~33, wherein **Ab** is an antibody or antigen binding fragment thereof that binds macrophage scavenger receptor 1 (MSR1).






~~76.~~35. ~~A~~ The compound of claim 2, wherein the compound is selected from the group consisting of


~~2b~~	
2f	
2g	
~~2j~~	
~~2k~~	
~~2l~~	

~~2m~~	
~~2n~~	 ~~or a mixture thereof~~
~~2q~~	
~~LP1~~	
~~LP2~~	


~~LP3~~	
~~LP4~~	
~~LP5~~	
~~LP6~~	
~~LP7~~	
~~LP8~~	

~~LP12~~	
~~LP13~~	
~~LP20~~	
~~LP21~~	
~~LP24~~	
~~LP25~~	

~~LP26~~	
~~LP27~~	
~~LP28~~	
~~LP29~~	
~~LP30~~	
~~and~~	

~~LP31~~	

~~77.~~36. A Compound according to Formula (**I**)



(**I**);


or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,

wherein

R^4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl;

a) both **R^x** are hydrogen or both **R^x** are fluoro; ~~and~~


R^3 is -C(O)**R^Z**; and ~~-(C_1-C_{10}-alkylene)-N**R^{50}**C(O)-(C_1-C_{10}-alkylene)-N**R^{50a}****R^{50b}**; -CH_2NH_2;~~



~~or~~ ;

R^Z is -C_{4-10}-alkylene-C(O)OH.~~; -(C_1-C_{10}-alkylene)-N**R^{50}**C(O)-(C_1-C_{10}-alkylene)-N**R^{50a}****R^{50b}**~~

~~where each C_1-C_{10}-alkylene is independently optionally substituted with one or more~~




~~hydroxy;~~ ~~; or N**R^{15}****R^{15a}**;~~


~~**R^{15}** is hydrogen or C_1-C_6alkyl and **R^{15a}** is -(C_1-C_{10}-alkylene)-SH or -(C_{1-6}-alkylene)-C(O)NHNH_2; or~~


~~b) both **R^x** are fluoro; and~~

~~**R^3** is -C(O)**R^Z**; -(C_1-C_{10}-alkylene)-N**R^{50}**C(O)-(C_1-C_{10}-alkylene)-N**R^{50a}****R^{50b}**; -CH_2NH_2; or~~



~~;~~

~~R^Z is C_{4-10}-alkylene-C(O)OH; $(C_1-C_{10}$-alkylene)-$NR^{50}C(O)$-$(C_1-C_{10}$-alkylene)-$NR^{50a}R^{50b}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy;~~  ~~; or $NR^{16}R^{16a}$;~~

~~R^{16} is hydrogen or C_1-C_6alkyl and R^{16a} is -$(C_1-C_{10}$-alkylene)-SH, -$(C_1-C_{10}$-alkylene)-NH_2, -$(C_1-C_{10}$-alkylene)-$NH(C_{1-6}$alkyl),~~  ~~, or -$(C_{1-6}$-alkylene)-$C(O)NHNH_2$; and~~

~~each R^{50}, R^{50a}, and R^{50b} are independently hydrogen or C_1-C_6-alkyl;~~

~~one of R^c, R^d, R^e, and R^f is $-CH_2OR^g$ and the others are independently hydrogen, -OH, hydroxyalkyl, -C(O)OH, or $-CH_2OR^g$, where each R^g is independently -$(C_{1-6}$-alkylene)-C(O)OH or -$(C_{1-6}$-alkylene)-C(O)O(alkyl); or one of R^c, R^d, R^e, and R^f is hydroxyalkyl and the others are hydrogen; and~~

~~**m** is zero to one.~~


~~78.~~37. The Compound of Claim ~~77~~36, where $\mathbf{R^4}$ is alkyl.

~~79.~~38. The Compound of Claim ~~77~~ 36 or ~~78~~37, where $\mathbf{R^4}$ is in the (*R*)-configuration.

~~80. The Compound of any one of claims 77-79, where~~

~~a) both R^x are hydrogen; and~~

~~R^3 is $-C(O)R^Z$; $(C_1-C_{10}$-alkylene)-$NR^{50}C(O)$-$(C_1-C_{10}$-alkylene)-$NR^{50a}R^{50b}$; or~~




~~;~~

~~R^Z is C_{4-10}-alkylene-C(O)OH; $(C_1-C_{10}$-alkylene)-$NR^{50}C(O)$-$(C_1-C_{10}$-alkylene)-$NR^{50a}R^{50b}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy; or $NR^{15}R^{15a}$;~~

~~R^{15} is hydrogen or C_1-C_6alkyl and R^{15a} is -$(C_1-C_{10}$-alkylene)-SH or -$(C_{1-6}$-alkylene)-$C(O)NHNH_2$; or~~


~~b) both R^x are fluoro; and~~


$\mathbf{R^3}$ is $-C(O)\mathbf{R^Z}$; $-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50}}C(O)-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50a}R^{50b}}$; or



;

$\mathbf{R^Z}$ is $-C_{4-10}$-alkylene-C(O)OH; $-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50}}C(O)-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50a}R^{50b}}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy; or $N\mathbf{R^{16}R^{16a}}$;


$\mathbf{R^{16}}$ is hydrogen or C_1-C_6alkyl and $\mathbf{R^{16a}}$ is $-(C_1-C_{10}\text{-alkylene})-SH$, $-(C_1-C_{10}\text{-alkylene})-NH_2$, $-(C_1-C_{10}\text{-alkylene})-NH(C_{1-6}\text{alkyl})$,  , or $-(C_{1-6}\text{-alkylene})-C(O)NHNH_2$.


81. The Compound of any one of Claims 77-79, where $\mathbf{R^3}$ is $-C(O)\mathbf{R^Z}$ and R^Z is  or $-CH_2NH_2$.


82. The Compound of any one of Claims 77-80, where $\mathbf{R^3}$ is $-C(O)\mathbf{R^Z}$.

83. The Compound of Claim 82, wherein $\mathbf{R^Z}$ is $-C_{4-10}$-alkylene-C(O)OH.

84. The Compound of Claim 82, wherein $\mathbf{R^Z}$ is $-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50}}C(O)-(C_1-C_{10}\text{-alkylene})-N\mathbf{R^{50a}R^{50b}}$ where each C_1-C_{10}-alkylene is independently optionally substituted with one or more hydroxy.

85. The Compound of any one of Claims 77-80, where $\mathbf{R^3}$ is  where **m** is one.

86. The Compound of any one of Claims 77-80, where $\mathbf{R^3}$ is  , **m** is one, and one of $\mathbf{R^c}$, $\mathbf{R^d}$, $\mathbf{R^e}$, and $\mathbf{R^f}$ is $-CH_2O\mathbf{R^g}$ and the others are independently hydrogen, –OH, or hydroxyalkyl.

87. The Compound of any one of Claims 77-80, where R^3 is , **m** is one, and one of R^c, R^d, R^e, and R^f is hydroxyalkyl and the others are hydrogen.

88. The Compound of any one of Claims 77-80, where R^3 is -(C_1-C_{10}-alkylene)-$NR^{50}C(O)$-(C_1-C_{10}-alkylene)-$NR^{50a}R^{50b}$.

89. The compound of any one of Claims 77-88, where both R^x are hydrogen.

90.39. The compound of any one of Claims 7736-8838, where both R^x are fluoro.




91. The Compound of any one of Claims 77-80, wherein both R^x are hydrogen, R^3 is -$C(O)R^Z$ and R^Z is $NR^{15}R^{15a}$.








92. The Compound of Claim 91, where R^{15} is hydrogen.






93. The Compound of any one of Claims 77-80, where both R^x are fluoro, R^3 is -$C(O)R^Z$ and R^Z is $NR^{16}R^{16a}$.

94. The Compound of Claim 93, where R^{16} is hydrogen.

95. A compound selected from the group consisting of


1e	
1g	
1h	

~~101a~~	
~~101b~~	
~~101c~~	
~~101d~~	
~~102c~~	
~~102d~~	
~~102e~~	


~~102f~~	
~~104a~~	
~~104b~~	
~~105a~~	 ~~and~~
~~105b~~	 ~~; or~~

~~a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.~~

~~96. A Compound selected from the group consisting of~~




and




or a mixture thereof;


where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

97. A Compound according to one of the following formulae







~~or a mixture thereof;~~





;




; and












~~or a mixture thereof~~





~~or a mixture thereof~~

~~where **BA** comprises an antibody or antigen binding fragment having the following structure~~




~~where **Ab** is a monoclonal antibody, polyclonal antibody, antibody fragment, or bispecific antibody; **R** is C_{2-4}-alkylene; and **n** is an integer selected from two to four, inclusive.~~

~~98. The compound of claim 96 or 97, wherein **Ab** or **BA** is an antibody or antigen binding fragment that binds macrophage receptor 1 (MSR1).~~


~~99.~~40. Use of a compound of Formula (III) of any one of claims 1~~-21 and 27-34, 63, or 68-75, or the compound of any one of claims 96-98~~ in the manufacture of a medicament for the

treatment of a disease, disorder, or condition associated with glucocorticoid receptor signaling wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.


~~100.~~41. The use of claim ~~99~~40, wherein side effects associated with administration of an unconjugated steroid payload of said compound are reduced.

~~101~~42. The Compound of claim 1, wherein for the Compound of Formula (**III**), **L** is -$\mathbf{L^1}$-$\mathbf{L^2}$-$\mathbf{L^3}$)$_{0\text{-}1}$-; **SP** is -C(O)-C_1-C_{10}-alkylene-C(O)-; and $\mathbf{L^3}$ is  where the -NH- group is attached to $\mathbf{L^2}$.


~~102. A Compound selected from the group consisting of~~




~~1c~~




~~1d~~




~~1e~~




~~1g~~




~~1h~~




~~1i~~




~~1j~~




~~101a~~




~~101b~~




~~101c~~




~~101d~~




~~102c~~




~~102d~~




~~102e~~



~~102f~~




~~104a~~ ~~and~~




~~104b~~

~~or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.~~


~~103. A Compound selected from the group consisting of~~




~~2a~~




~~2b~~




~~2c~~




~~2d~~




~~2e~~




~~2f~~




~~2g~~




~~2j~~




~~2k~~




~~2l~~




~~2m~~




~~2n~~




~~2q~~




~~2r~~




~~2s~~




~~LP1~~




~~LP2~~




~~LP3~~




~~LP4~~




~~LP5~~




~~LP6~~




~~LP7~~




~~LP8~~




~~LP12~~



~~LP13~~




~~LP20~~ and




~~LP21~~


~~or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.~~

~~1044~~3. ~~A~~ The Compound of claim 1 selected from the group consisting of







;




; and


Ab
H
N
N
N
N
O
O
NH
O
O
O



z ~~; and~~




z ;


wherein **Ab** is an antibody or an antigen binding fragment thereof; and


z is an integer from one to four.

~~105. A Compound selected from the group consisting of~~




z ~~;~~



Ab
H
N
O
N
N
N
O
O
O
O
O
O
NH
O
O
O
O
O
O




;




;





;







;








;



Ab
H
N
O
N
N
N
O
O
O



Ab
H
N
O
N
N
N
O
O
O



Ab
N
H
O
S
S
N
H
O
O
O
O
H
H
H
F
F
HO
O
z


Ab
N
H
O
S
S
N
O
O
O
O
H
H
H
F
F
HO
O
z



Ab
N
H
O
O
O
O
O
O
O
O
N
N
N
H
O
NH
O
O
N
H
O
S
S
N
H
O
O
O
O
H
H
H
F
F
HO
O
z


Ab
N
H
O
NH
S
S
F
HO
z



Ab
N
H
O
NH
NH
NH2
F
HO
z



;



; and


Ab
N
H
O
N
N
H
H
O
O
O